Mr. Piot started his career at Banque Worms in Hong Kong in 1994 as a financial analyst before joining corporate finance teams at Crédit Lyonnais Hong Kong Branch. In 1997, he joined the Equity Capital Market (ECM) team at Crédit Lyonnais in Paris as Project Manager. In 2000, he joined Oddo & Cie, where he specialized in IPO operations for high-growth companies, then went to Natixis as part of the ECM team.
In October 2007, Mr. Piot became CFO of French biotech Ipsogen that develops and commercializes molecular diagnostic tools. He led the company's IPO on Alternext in Paris as well as subsequent fundraising to finance the development of the company.
Mr. Piot is a graduate of the University of Paris and holds a Master's degree in economics and finance.
A new generation of stents
Stentys offers a new generation of stents, which are specifically designed for the treatment of Acute Myocardial Infarction (AMI). These revolutionary self-apposing stents offer a safer treatment option for patients by adapting exactly to the changes in diameter of the coronary arteries during the post-AMI phase. Stentys stents have been introduced in response to cardiologists' demands for improved stent solutions for AMI, a major cardiovascular pathology which is widespread across western countries.
The results for the Apposition II study will be announced in September. This study was designed to compare a Stentys stent to a conventional coronary stent in the treatment of Acute Myocardial Infarction.
About Stentys
Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents for the treatment of acute myocardial infarction (AMI). Stentys was founded by Jacques Séguin, M.D., Ph.D., (founder of CoreValve, which was acquired last year by Medtronic for $700 million) and by Gonzague Issenmann. Stentys received CE Mark for its flagship products in 2010 and will start the pre-release phase in selected European countries. Institutional shareholders are Sofinnova Partners, Crédit Agricole Private Equity and Scottish Equity Partners.
